About
Myelorin is an independent resource on the emerging science, limits, and safety questions surrounding ibogaine and multiple sclerosis. We open with evidence: outcome-focused summaries and transparent sourcing so readers can weigh hypotheses against established clinical evidence.
Before: Fragmented, speculative summaries
Readers previously had to patch together clinical reports, anecdotal accounts, and isolated lab studies to get a sense of mechanistic claims. That made it difficult to distinguish promising mechanistic hypotheses from established clinical evidence.
After: Centralized evidence context
We present outcome-focused summaries, before/after style explanatory panels, and clear citations so early-stage hypotheses about mechanisms are framed with their limits and safety considerations.
Our editorial approach
Myelorin curates and synthesizes published work, registry reports, and official guidance to make mechanistic claims readable and testable. We do not provide clinical advice or treatment; our role is information synthesis and clarity.
How we source and vet content
We prioritize primary literature, trial registries and official guidance. For methodological claims we cross-check registry entries and peer-reviewed studies; for safety context we consult authoritative sources such as the U.S. National Institutes of Health and established clinical registries when available. For instance, government health information and respected university resources often provide protocol and safety frameworks useful to readers (NIH).
When we reference historical or scientific context we may link to concise, reliable secondary summaries such as the relevant overview on Wikipedia's Multiple Sclerosis entry to orient readers — these are used only as general context, not as primary evidence.
We also draw on established systematic-review methods when summarizing bodies of literature; these approaches align with standards taught at major research universities (Harvard University).
What we cover
Myelorin focuses on explaining mechanistic hypotheses, summarizing safety-related evidence, and cataloguing limits in the literature so patients, families, and professionals can see where consensus exists and where uncertainty remains. Our pieces are organized as explanatory primers, evidence breakdowns, and safety-focused briefs.
For readers seeking treatment-provider directories or clinical services, we explicitly point to independent specialist directories rather than providing referral or endorsement; for example, some organizations maintain treatment listings that are operationally distinct from our editorial mission (ibogaine treatment directories).
Who this is for
Myelorin serves patients and families seeking a clearer view of research claims, and professionals or curious readers who want an evidence-first summary. We aim to reduce confusion by providing transparent sourcing and clear statements of uncertainty.
How to navigate the site
Start with our primers for conceptual background, then review evidence breakdowns for study-level summaries and methods. If you're interested in the site's editorial services or bespoke evidence reviews we offer explanatory information on our services page describing how we work with external partners.
Independent by design
We maintain independence from treatment providers and commercial interests to prioritize clarity and safety. If you need clinical care or advice, consult a licensed medical professional; our content is informational only.